Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -
- The Company will host its first virtual medical symposium at CTOS -
- Translational data from Phase 1 SURPASS trial to be presented at SITC -
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will present clinical and translational data from the Phase 2 SPEARHEAD-1 trial at the Connective Tissue Oncology Society (CTOS) meeting. The Company will also present translational data based on the patients for whom safety and efficacy were recently reported at ESMO from the Phase 1 SURPASS trial, as well as a data update from the four patients treated in the Radiation sub-study of the Phase 1 trial with afami-cel, at the Society for Immunotherapy of Cancer (SITC) meeting. Abstracts are available online on the meetings’ web sites.
“At CTOS, we will present clinical and translational data updates from our SPEARHEAD-1 trial. Data from this trial will form the basis of our first BLA submission next year for afami-cel in synovial sarcoma and MRCLS,” said Elliot Norry, Adaptimmune’s Chief Medical Officer. “During SITC, we will present translational data from the SURPASS trial with our next-gen therapy ADP-A2M4CD8, as well as clinical data from a sub-study combining low-dose radiation with afami-cel. These two trials represent investigational approaches to improving the potency of our SPEAR T-cells. Understanding how we can continually enhance our T-cell therapies, so as to ultimately improve clinical outcomes for patients, is a key focus of our translational and early phase clinical research.”
Abstract Title: SPEARHEAD-1: A Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (Abstract #1080870)
Oral presentation: November 12, 2021, in the Immunotherapy & Immune Microenvironment Session starting at 10:00 a.m. EST. Presenter: Dr. Brian Van Tine, Associate Professor of Medicine at Washington University School of Medicine in St. Louis
Abstract Title: SPEARHEAD-1 preliminary translational insights from a Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (Abstract #1080366)
Poster Presentation: November 12, 2021, 2:30 p.m. – 3:15 p.m. EST during the Immunology & Immunotherapy Session. Presenter: Dr. Sandra D’Angelo, Medical Oncologist at Memorial Sloan Kettering Cancer Center
At CTOS, Adaptimmune will host its first virtual medical symposium on Thursday, November 11, 4:30-6:30 p.m. EST.
Abstract Title: Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion (Abstract #373)
Poster presentation: November 12-14, 2021, 7:00 a.m – 5:00 p.m. EST. Presenter: Alex Tipping, Adaptimmune
Abstract Title: Radiation sub-study to characterize safety and tolerability of low-dose radiation in combinations with afami-cel in patients with advanced cancers (Abstract #376)
Poster Presentation: November 12-14, 2021, 7:00 a.m. - 5:00 p.m. EST. Presenter: Dr. James W. Welsh, Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 9, 2021 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Sébastien Desprez — VP, Corporate Affairs and Communications
T: +44 1235 430 583
M: +44 7718 453 176
Juli P. Miller, Ph.D. — VP, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Released October 5, 2021